Dirk Pleimes

1.1k total citations
28 papers, 659 citations indexed

About

Dirk Pleimes is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dirk Pleimes has authored 28 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pathology and Forensic Medicine and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dirk Pleimes's work include Multiple Sclerosis Research Studies (9 papers), Neutropenia and Cancer Infections (5 papers) and Blood disorders and treatments (4 papers). Dirk Pleimes is often cited by papers focused on Multiple Sclerosis Research Studies (9 papers), Neutropenia and Cancer Infections (5 papers) and Blood disorders and treatments (4 papers). Dirk Pleimes collaborates with scholars based in Germany, United States and United Kingdom. Dirk Pleimes's co-authors include Xavier Montalbán, Ludwig Kappos, Rupert Sandbrink, Frederik Barkhof, Christoph Pohl, Gilles Edan, Mark S. Freedman, Chris H. Polman, Hans‐Peter Hartung and David H. Miller and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Dirk Pleimes

23 papers receiving 637 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dirk Pleimes Germany 11 496 165 105 105 77 28 659
Barbara Teter United States 13 413 0.8× 82 0.5× 94 0.9× 135 1.3× 107 1.4× 28 656
Marja‐Liisa Sumelahti Finland 16 653 1.3× 179 1.1× 125 1.2× 145 1.4× 114 1.5× 45 911
Stine Marit Moen Norway 15 469 0.9× 139 0.8× 86 0.8× 88 0.8× 75 1.0× 26 611
Wolfgang Feneberg Germany 12 293 0.6× 105 0.6× 143 1.4× 59 0.6× 113 1.5× 25 513
Amer Awad United States 7 285 0.6× 81 0.5× 127 1.2× 81 0.8× 45 0.6× 14 430
KG Simon United States 6 746 1.5× 355 2.2× 77 0.7× 153 1.5× 104 1.4× 9 981
Filipe Palavra Portugal 12 592 1.2× 85 0.5× 235 2.2× 196 1.9× 147 1.9× 44 921
Z Lević Serbia 14 339 0.7× 71 0.4× 154 1.5× 145 1.4× 96 1.2× 42 576
Roberta Bedin Italy 16 299 0.6× 69 0.4× 230 2.2× 136 1.3× 123 1.6× 42 710
Ziyan Shi China 15 427 0.9× 90 0.5× 346 3.3× 115 1.1× 110 1.4× 74 701

Countries citing papers authored by Dirk Pleimes

Since Specialization
Citations

This map shows the geographic impact of Dirk Pleimes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Pleimes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Pleimes more than expected).

Fields of papers citing papers by Dirk Pleimes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Pleimes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Pleimes. The network helps show where Dirk Pleimes may publish in the future.

Co-authorship network of co-authors of Dirk Pleimes

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Pleimes. A scholar is included among the top collaborators of Dirk Pleimes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Pleimes. Dirk Pleimes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Evans, Jillian F., et al.. (2024). Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis. Biomolecules. 14(10). 1236–1236. 2 indexed citations
2.
Pleimes, Dirk, et al.. (2024). TPT‐004, a Next‐Generation Inhibitor of Tryptophan Hydroxylase, Ameliorates Pulmonary Arterial Hypertension in Rats. Journal of the American Heart Association. 13(10). e034240–e034240. 2 indexed citations
3.
Schüle, Simone, Patrick Ostheim, Cornelius Hermann, et al.. (2022). Four Genes Predictive for the Severity of Hematological Damage Reveal a Similar Response after X Irradiation and Chemotherapy. Radiation Research. 199(2). 115–123. 5 indexed citations
4.
Specker, Edgar, Susann Matthes, Anja Schütz, et al.. (2022). Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and Potent Tryptophan Hydroxylase Inhibitors. Journal of Medicinal Chemistry. 65(16). 11126–11149. 10 indexed citations
5.
6.
Pleimes, Dirk, et al.. (2018). Effects of a Novel Orally Bioavailable Small Molecule (Imidazolyl Ethanamide Pentandioic Acid) on Acute Radiation Syndrome. Blood. 132(Supplement 1). 5089–5089. 1 indexed citations
7.
Ernst, Frank R., Jennifer Pocoski, Gary Cutter, David W. Kaufman, & Dirk Pleimes. (2015). Analysis of Diagnoses Associated with Multiple Sclerosis–Related In-Hospital Mortality Using the Premier Hospital Database. International Journal of MS Care. 18(3). 154–161. 5 indexed citations
8.
9.
Goodin, Douglas S., Michael J. Corwin, David W. Kaufman, et al.. (2014). Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States. PLoS ONE. 9(8). e105207–e105207. 30 indexed citations
10.
Pleimes, Dirk, et al.. (2014). Effect of IEPA, a Novel Orally Bioavailable Small Molecule, on Chemotherapy-Induced Myelosuppression. Blood. 124(21). 4355–4355. 1 indexed citations
11.
Ascherio, Alberto, Kassandra L. Munger, Rick White, et al.. (2014). Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurology. 71(3). 306–306. 360 indexed citations
12.
Kaufman, David W., Howard L. Golub, Mark Peucker, et al.. (2013). Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.. Multiple Sclerosis and Related Disorders. 3(3). 364–371. 26 indexed citations
13.
Corwin, Michael J., Howard L. Golub, Gary Cutter, et al.. (2013). Subcategory Analysis of Causes of Death in Patients with Multiple Sclerosis from a Large US Insurance Database (S30.007). Neurology. 80(7_supplement).
14.
Edan, Gilles, Ludwig Kappos, Xavier Montalbán, et al.. (2013). Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Journal of Neurology Neurosurgery & Psychiatry. 85(11). 1183–1189. 57 indexed citations
15.
Pohl, Christoph, Mike P. Wattjes, Hanneke E. Hulst, et al.. (2013). Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis Journal. 20(2). 234–242. 17 indexed citations
16.
Pan, Feng, et al.. (2012). Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States. Clinical Therapeutics. 34(9). 1966–1976. 18 indexed citations
17.
Penner, Iris‐Katharina, Brigitte Stemper, Pasquale Calabrese, et al.. (2012). Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Sclerosis Journal. 18(10). 1466–1471. 44 indexed citations
18.
Kappos, Ludwig, Xavier Montalbán, C. Polman, et al.. (2011). Long-term effect of early treatment with interferon-beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year observational extension of the phase 3 BENEFIT trial. UCL Discovery (University College London). 1 indexed citations
19.
Groneberg‐Kloft, Beatrix, et al.. (2007). Analysis and evaluation of environmental tobacco smoke exposure as a risk factor for chronic cough. PubMed. 3(1). 6–6. 11 indexed citations
20.
Springer, Jochen, Dirk Pleimes, Frank Scholz, & Axel Fischer. (2004). Substance P mediates AP-1 induction in A549 cells via reactive oxygen species. Regulatory Peptides. 124(1-3). 99–103. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Teter Breakdown of academic impact, for papers by Marja‐Liisa Sumelahti Breakdown of academic impact, for papers by Stine Marit Moen Breakdown of academic impact, for papers by Wolfgang Feneberg Breakdown of academic impact, for papers by Amer Awad Breakdown of academic impact, for papers by KG Simon Breakdown of academic impact, for papers by Filipe Palavra Breakdown of academic impact, for papers by Z Lević Breakdown of academic impact, for papers by Roberta Bedin Breakdown of academic impact, for papers by Ziyan Shi
Rankless by CCL
2026